Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 20/20 | 0.45 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.44 |
| ▸ | MAP3K6 | O95382 | 2/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
| ▸ | MERTK | Q12866 | 1/20 | 0.44 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15136088 | 0.88 | MAP3K5 (0.56) | MAP3K5MAP3K7MAP3K6RETCDK2 | |
| SCHEMBL29506348 | 0.88 | MAP3K5 (0.56) | MAP3K5MAP3K7MAP3K6RETCDK2 | |
| SCHEMBL21724100 | 0.85 | MAP3K5 (0.45) | MAP3K5MAP3K7MAP3K6RETCDK2 | |
| SCHEMBL21724101 | 0.85 | MAP3K5 (0.45) | MAP3K5MAP3K7MAP3K6RETCDK2 | |
| SCHEMBL20523136 | 0.85 | MAP3K5 (0.58) | MAP3K5MAP3K7MAP3K6CDK2 | |
| SCHEMBL30269941 | 0.85 | MAP3K5 (0.58) | MAP3K5MAP3K7MAP3K6CDK2 | |
| SCHEMBL20523134 | 0.85 | MAP3K5 (0.58) | MAP3K5MAP3K7MAP3K6CDK2 | |
| SCHEMBL29217677 | 0.85 | MAP3K5 (0.58) | MAP3K5MAP3K7MAP3K6CDK2 | |
| SCHEMBL30269903 | 0.83 | MAP3K5 (0.50) | MAP3K5MAP3K7MAP3K6RETCDK2 | |
| SCHEMBL21724372 | 0.83 | MAP3K5 (0.48) | MAP3K5MAP3K7MAP3K6RETCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110407806-B | Carboxamide compounds, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20210139454-A1 | FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2021-05-13 | — | — | US | disclosed |
| EP-3789384-A1 | FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2021-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139454-A1 | FORMAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WEE1, WEE2, MAP3K11 | MAP3K5 12/4885MAP3K7 16/4885MAP3K6 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.